CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations

CorMedix Inc. (NASDAQ:CRMD) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents.Sales reached $104.27 million, a jump from $11.5 million a year ago, beating the consensus of $86.02 million.Net revenue of $104.3 million and pro forma net revenue of $130.8 million were primarily driven by higher-than-expected utilization of DefenCath by its outpatient dialysis customers.DefenCath sales contributed $88.8 million of net revenue in the quarter.The company recognized ...